Objective:

To summarize recent advancements and acquisitions in CAR-T therapies and gene therapies.

Approach:

Key Findings:

• Lilly's acquisition aims to simplify CAR-T delivery and improve access.
• Otarmeni shows 80% of patients achieving meaningful hearing improvement.
• Mivocabtagene autoleucel leads to significant mobility improvements in stiff person syndrome.
• NRTX-1001 targets overactive neural circuits in epilepsy with early promising data.
• Cilta-cel achieves MRD negativity in all patients with high-risk smoldering multiple myeloma.
• AIC100 shows early responses in advanced thyroid cancers with manageable safety profile.

Interpretation:

These developments indicate a significant shift towards innovative therapies that enhance patient access and treatment efficacy in various conditions.

Limitations:

• Early-phase trials may not fully predict long-term outcomes.
• Limited patient populations in trials may affect generalizability.

Conclusion:

The advancements in CAR-T and gene therapies reflect a growing trend towards personalized and accessible treatments for complex diseases.

Source

Based on findings from:

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

The Medicine Maker, 2026.

https://www.themedicinemaker.com/issues/2026/articles/april/this-weeks-cgt-news-lillys-7b-in-vivo-cart-bet/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.